- Home
- CLMT vs AUPH Comparison
CLMT vs AUPH Comparison
Compare CLMT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLMT | AUPH |
|---|---|---|
| Founded | 1916 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2006 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CLMT | AUPH |
|---|---|---|
| Price | $20.25 | $14.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.45 | $17.25 |
| AVG Volume (30 Days) | 933.9K | ★ 994.1K |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $4,048,000,000.00 | $265,808,000.00 |
| Revenue This Year | $0.23 | $21.76 |
| Revenue Next Year | $3.14 | $16.45 |
| P/E Ratio | ★ N/A | $27.00 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $7.68 | $6.55 |
| 52 Week High | $22.10 | $16.54 |
Technical Indicators
Market Signals| Indicator | CLMT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 40.90 |
| Support Level | $19.29 | $14.74 |
| Resistance Level | $21.27 | $15.28 |
| Average True Range (ATR) | 0.75 | 0.50 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 69.79 | 7.25 |
Price Performance
Historical ComparisonAbout CLMT Calumet Specialty Products Partners L.P.
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.